Therapy in hidradenitis suppurativa

There is currently an unmet need for new treatments for hidradenitis suppurativa (HS)

The authors of this prospective, randomised, double-blind, placebo-controlled study in Denmark investigated the efficacy of adalimumab in the treatment of HS. Twenty-one patients were randomised two to one to active treatment with adalimumab 80mg subcutaneously at baseline followed by 40mg subcutaneously every other week for 12 weeks (n = 15) or placebo (n = 6).

After six weeks, a significant reduction in severity of HS was seen and after 12 weeks, the reduction was almost significant. Adalimumab therefore reduces the severity of HS and improves quality of life in patients with this chronic inflammatory disease, the researchers say.
Miller I, Lynggaard CD, Lophaven S et al. Br J Dermatol 2011; 165: 391-8

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Therapeutic options in hidradenitis suppurativa

Therapeutic options in hidradenitis suppurativa

This condition can have a severe impact on quality...

Case Study: Hidradenitis suppurativa

The case A 25-year-old woman presented with a history...

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases